Abstract
CS1 (also known as CD319, CRACC and SLAMF7) was identified as an NK cell receptor regulating immune functions. It is also expressed on B cells, T cells, Dendritic cells, NK-T cells, and monocytes. CS1 is overexpressed in multiple myeloma and makes it a target for immunotherapy. A humanized anti-CS1 antibody, Elotuzumab or Empliciti has shown promising results in clinical studies. This review focuses on the biology of CS1 in NK and other hematopoietic cells and multiple myeloma. Anti-CS1 mAb can activate natural cytotoxicity of NK cells as well as enhance ADCC (antibody-dependent cell-mediated cytotoxicity) and thus makes an effective target for immunotherapy of MM.
| Original language | English |
|---|---|
| Pages (from-to) | 1637-1641 |
| Number of pages | 5 |
| Journal | American Journal of Cancer Research |
| Volume | 7 |
| Issue number | 8 |
| State | Published - 1 Jan 2017 |
Keywords
- Antibody-based immunotherapy
- CRACC
- CS1
- Elotuzumab
- Multiple myeloma
- SLAMF7